Odimma Therapeutics

Executive Summary

Odimma Therapeutics is a Paris-based biotechnology company founded in 2021, focused on developing a next-generation personalized immunotherapy platform for cancer treatment. By leveraging artificial intelligence and synthetic DNA technology, the company aims to create unique therapies tailored to an individual patient's tumor. The platform combines advanced computational modeling with synthetic biology to design and produce customized antibody-based biologics and gene therapies. Odimma's approach targets the specific mutational profile of each patient's cancer, potentially improving efficacy and reducing side effects compared to conventional immunotherapies. The company operates at the intersection of antibodies, biologics, RNA and gene therapy, and viral technology, reflecting a multi-modal strategy. While still in early stages, Odimma's innovative platform has the potential to address key limitations of current cancer immunotherapy, including resistance and lack of response in certain tumor types. The company is privately held and has not disclosed funding amounts or valuation, but its focus on AI-driven personalized medicine aligns with industry trends toward precision oncology.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data for lead candidate40% success
• Q2 2026Series A financing round60% success
• Q4 2026Partnership or licensing deal with major pharma30% success